Valneva Says Single-Dose Chikungunya Vaccine IXCHIQ Showed Antibody Persistence Consistent With Prior Results, In Line With Company Expectations, With 94% Seroresponse At Year 5 Across Age Groups

Benzinga · 2d ago
  • 94% of participants maintained seroresponse five years after a single vaccination
  • Comparable antibody persistence observed in older (65+) and younger adults
  • Data further reinforce IXCHIQ®'s differentiated profile with durable antibody persistence against an unpredictable outbreak disease